MAIA Expands Phase 2 Trial for Telomere-Targeting Cancer Drug at Emory’s Winship — MAIA Biotechnology, Inc.

Event summary

MAIA Biotechnology activated its third U.S. clinical site for the Phase 2 THIO-101 expansion trial at Emory’s Winship Cancer Institute on June 18, 2026.
The trial evaluates ateganosine, a novel telomere-targeting agent, as a third-line treatment for non-small cell lung cancer (NSCLC).
Winship is Georgia’s only NCI-designated Comprehensive Cancer Center, with over 7,300 new lung cancer cases reported in Georgia in 2025.
Early trial results showed some patients surviving beyond two years, prompting the expansion of the study.

The big picture

MAIA’s expansion into Winship Cancer Institute strengthens its clinical footprint in a key oncology hub, addressing a critical unmet need in third-line NSCLC treatment. The trial’s focus on telomere-targeting represents a strategic shift toward precision immuno-oncology, potentially reshaping treatment paradigms for resistant cancers. Success here could position MAIA as a leader in next-generation cancer therapies.

What we're watching

Trial Execution: Whether MAIA can sustain patient enrollment and demonstrate consistent efficacy across multiple sites.
Regulatory Pathway: The pace at which ateganosine advances toward potential FDA approval, given its novel mechanism of action.
Competitive Positioning: How ateganosine’s telomere-targeting approach differentiates it from existing NSCLC treatments.